Peptide inhibitors of protein kinasesβdi
β
Marie A. Bogoyevitch; Renae K. Barr; Albert J. Ketterman
π
Article
π
2005
π
Elsevier Science
π
English
β 463 KB
Protein kinases are now the second largest group of drug targets, and most protein kinase inhibitors in clinical development are directed towards the ATP-binding site. However, these inhibitors must compete with high intracellular ATP concentrations and they must discriminate between the ATP-binding